Protara Therapeutics, Inc.
Protara Therapeutics, Inc. (TARA): 18 pipeline candidates · 5 upcoming catalysts · ~19 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
18.5 months
D/E 0.06 · 5% dilution
Lead: Phase 2/Phase 3
18 candidates
5 upcoming, next in ~714d
0 buys · 2 sells (180d)
A transparent, data-derived signal for Protara Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$215.8M
Cash
$15.5M
Quarterly Burn
$21.3M
Runway
18.5 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (18 candidates)
| Drug | Phase |
|---|---|
| choline | Phase 2/Phase 3 |
| choline | Phase 2/Phase 3 |
| choline | Phase 2/Phase 3 |
| choline | Phase 2/Phase 3 |
| choline | Phase 2/Phase 3 |
| choline | Phase 2/Phase 3 |
| choline | Phase 2/Phase 3 |
| choline | Phase 2/Phase 3 |
| choline | Phase 2/Phase 3 |
| choline | Phase 2/Phase 3 |
Showing 10 of 18 candidates. Sign up for full pipeline.
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
110
Total value held
$236.2M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 10,414,022 | $54.3M |
| vanguard capital management llc | 4,238,036 | $22.1M |
| blackrock, inc. | 3,394,968 | $17.7M |
| millennium management llc | 2,831,208 | $14.8M |
| blackstone inc. | 2,265,514 | $11.8M |
| acorn capital advisors, llc | 1,752,115 | $9.1M |
| ubs group ag | 1,402,413 | $7.3M |
| 5am venture management, llc | 1,369,782 | $7.1M |
| citadel advisors llc | 1,232,458 | $6.4M |
| geode capital management, llc | 1,177,200 | $6.1M |
Showing top 10 of 110 institutional holders of Protara Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Protara Therapeutics, Inc.'s pipeline?
Protara Therapeutics, Inc. (TARA) has 18 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Protara Therapeutics, Inc.'s lead drug candidate?
Protara Therapeutics, Inc.'s most advanced tracked candidate is choline (Phase 2/Phase 3) for Choline Deficiency.
What is Protara Therapeutics, Inc.'s next catalyst?
Protara Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 2b/3 Randomized Open-Label Dose-Selection Study With Open-Label Extension and Randomized Dou" — expected June 1, 2028.
What is Protara Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Protara Therapeutics, Inc. has approximately 18.5 months of cash runway.
What is Protara Therapeutics, Inc.'s market capitalization?
Protara Therapeutics, Inc.'s market capitalization is approximately $215.8M.
Get the full picture on Protara Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.